ZY0511, a novel, potent and selective LSD1 inhibitor, exhibits anticancer activity against solid tumors via the

Yan Li1, Lei Tao1, Zeping Zuo1

  • 1State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, and Collaborative Innovation Center for Biotherapy, Sichuan University, Chengdu, 610041, China.

Cancer Letters
|April 13, 2019
PubMed

Insights

A novel drug, ZY0511, effectively inhibits lysine-specific demethylase 1 (LSD1) and cancer cell growth. It works by increasing DDIT4, a suppressor of mTORC1, showing therapeutic potential for solid tumors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Epigenetics

Background:

  • Lysine-specific demethylase 1 (LSD1) is implicated in cancer development but its mechanisms are not fully understood.
  • There is a need for more effective LSD1 inhibitors for cancer therapy.
  • Understanding LSD1's role in oncogenesis is crucial for targeted treatment strategies.

Purpose of the Study:

  • To investigate the biological activity of a novel LSD1 inhibitor, ZY0511.
  • To elucidate the mechanism of action of ZY0511 in cancer cells.
  • To evaluate the therapeutic potential of ZY0511 in preclinical models.

Main Methods:

  • Assessed LSD1 inhibition and cancer cell proliferation in vitro.
  • Utilized ChIP-PCR to confirm DDIT4 as a direct downstream target of LSD1.
  • Investigated the effect of ZY0511 on histone methylation and mTORC1 activity.
  • Evaluated ZY0511 efficacy and toxicity in mouse xenograft models.

Main Results:

  • ZY0511 specifically inhibited LSD1 activity and proliferation in various cancer cells, notably HeLa and HCT116.
  • ZY0511 upregulated DDIT4 expression by altering histone H3K4 methylation at the DDIT4 promoter, suppressing mTORC1.
  • Knockdown of DDIT4 diminished ZY0511's anti-cancer effects.
  • ZY0511 treatment significantly inhibited tumor growth in xenograft models with no detectable toxicity.
  • DDIT4 expression correlated with sensitivity to chemotherapy.

Conclusions:

  • ZY0511 demonstrates significant therapeutic potential for solid tumors by inhibiting LSD1 and modulating the DDIT4/mTORC1 pathway.
  • The induction of DDIT4 by ZY0511 offers a potential predictive biomarker for LSD1 inhibitor efficacy.
  • Further research into ZY0511 and its downstream effects could lead to novel cancer treatments.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.4K
Metallic Solids02:37

Metallic Solids

Metallic solids such as crystals of copper, aluminum, and iron are formed by metal atoms. The structure of metallic crystals is often described as a uniform distribution of atomic nuclei within a “sea” of delocalized electrons. The atoms within such a metallic solid are held together by a unique force known as metallic bonding that gives rise to many useful and varied bulk properties.
All metallic solids exhibit high thermal and electrical conductivity, metallic luster, and malleability....
20.5K
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
14.8K
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
10.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.7K
Molecular and Ionic Solids02:54

Molecular and Ionic Solids

Crystalline solids are divided into four types: molecular, ionic, metallic, and covalent network based on the type of constituent units and their interparticle interactions.
Molecular Solids
Molecular crystalline solids, such as ice, sucrose (table sugar), and iodine, are solids that are composed of neutral molecules as their constituent units. These molecules are held together by weak intermolecular forces such as London dispersion forces, dipole-dipole interactions, or hydrogen bonds, which...
20.0K